BioNTech
stock was falling Monday despite solid quarterly earnings from the German biotech group. Investors were focused on the company’s outlook this year for Covid-19 vaccine sales.
Shares in BioNTech (ticker: BNTX) shed 2% in premarket trading on Monday after the company reported fourth-quarter earnings of €9.26 ($9.97) a share on revenue of €4.28 billion. That’s well ahead of the profit of €7.78 a share on revenue of €3.65 billion expected among analysts surveyed by FactSet.
Source: https://www.barrons.com/articles/biontech-stock-earnings-covid-vaccine-95a3831e?siteid=yhoof2&yptr=yahoo